PepGen Raises $115M to Advance Neuromuscular Therapies

PepGen has raised $115,000,000 in a recent funding round, securing significant investment capital from a syndicate of investors. The biotechnology firm is dedicated to developing novel disease-modifying therapeutics for serious genetic disorders. Driven by its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. This substantial capital infusion underscores investor confidence in PepGen’s innovative EDO platform and its potential to address significant unmet medical needs within these challenging therapeutic areas. The funding validates the company's scientific approach and its progress in the biotechnology landscape. PepGen plans to deploy the newly secured funds to significantly accelerate its research and development efforts. A primary focus will be on further expanding its proprietary EDO platform and advancing its pipeline of therapeutic candidates towards clinical milestones. The investment is expected to enable the company to scale its operational capabilities, strengthen its scientific team, and accelerate its mission to bring transformative treatments to patients suffering from devastating genetic conditions. This funding round represents a pivotal moment for PepGen, positioning the company for substantial growth and continued innovation. PepGen remains committed to translating its scientific breakthroughs into meaningful clinical outcomes, aiming to broaden its therapeutic reach and make a significant impact on global health.